**LISTA DE ARTÍCULOS SOBRE ALZHEIMER Y PROTEÓMICA SIN LAS REVISIONES BIBLIOGRÁFICAS ENCONTRADAS**

|  |  |
| --- | --- |
| 1. Quantitative proteomic profiling of cerebrospinal fluid to identify candidate biomarkers for alzheimer's disease. 2. [Alzheimer disease pathology and the cerebrospinal fluid proteome.](https://www.ncbi.nlm.nih.gov/pubmed/30021611) 3. [The emif-ad multimodal biomarker discovery study: design, methods and cohort characteristics.](https://www.ncbi.nlm.nih.gov/pubmed/29980228) 4. [Brain-related proteins as potential csf biomarkers of alzheimer's disease: a targeted mass spectrometry approach.](https://www.ncbi.nlm.nih.gov/pubmed/29684683) 5. Identification of prefrontal cortex protein alterations in alzheimer's disease. 6. A parallel reaction monitoring mass spectrometric method for analysis of potential csf biomarkers for alzheimer's disease. | **2018** |
| 1. [Plasma proteomic profiles of cerebrospinal fluid defined alzheimer's disease pathology in older adults.](https://www.ncbi.nlm.nih.gov/pubmed/29125490) 2. A novel quantification-driven proteomic strategy identifies an endogenous peptide of pleiotrophin as a new biomarker of alzheimer's disease. 3. A simplified and sensitive method to identify alzheimer's disease biomarker candidates using patient-derived induced pluripotent stem cells (ipscs). 4. Mass spectrometric analysis of cerebrospinal fluid ubiquitin in alzheimer's disease and parkinsonian disorders. 5. Metabolic network failures in alzheimer's disease: a biochemical road map. 6. Selenium levels in serum, red blood cells, and cerebrospinal fluid of alzheimer's disease patients: a report from the australian imaging, biomarker &amp; lifestyle flagship study of ageing (aibl). 7. Plasma protein profiling for potential biomarkers in the early diagnosis of alzheimer's disease. 8. Improved cerebrospinal fluid-based discrimination between alzheimer's disease patients and controls after correction for ventricular volumes. 9. Expanding the cerebrospinal fluid endopeptidome. 10. Identification of discriminative imaging proteomics associations in alzheimer's disease via a novel sparse correlation model. 11. Alpha-2 macroglobulin in alzheimer's disease: a marker of neuronal injury through the rcan1 pathway. 12. Combined tissue and fluid proteomics with tandem mass tags to identify low-abundance protein biomarkers of disease in peripheral body fluid: an alzheimer's disease case study. | **2017** |
| 1. Identification of blood biomarkers for use in point of care diagnosis tool for alzheimer's disease. 2. Label-free quantitative comparison of cerebrospinal fluid glycoproteins and endogenous peptides in subjects with alzheimer's disease, mild cognitive impairment, and healthy individuals. 3. A targeted proteomic multiplex csf assay identifies increased malate dehydrogenase and other neurodegenerative biomarkers in individuals with alzheimer's disease pathology. 4. CSF profiling of the human brain enriched proteome reveals associations of neuromodulin and neurogranin to alzheimer's disease. 5. Alpha-, beta-, and gamma-synuclein quantification in cerebrospinal fluid by multiple reaction monitoring reveals increased concentrations in alzheimer's and creutzfeldt-jakob disease but no alteration in synucleinopathies. 6. Amyloid-beta oligomerization is associated with the generation of a typical peptide fragment fingerprint. 7. Analysis of the cerebrospinal fluid proteome in alzheimer's disease. 8. Oxidative signature of cerebrospinal fluid from mild cognitive impairment and alzheimer disease patients. 9. CSF n-glycoproteomics for early diagnosis in alzheimer's disease. 10. Novel diagnostic cerebrospinal fluid biomarkers for pathologic subtypes of frontotemporal dementia identified by proteomics. | **2016** |
| 1. Expanding the repertoire of biomarkers for alzheimer's disease: targeted and non-targeted approaches. 2. [Identification of novel csf biomarkers for neurodegeneration and their validation by a high-throughput multiplexed targeted proteomic assay.](https://www.ncbi.nlm.nih.gov/pubmed/26627638) 3. Isobaric quantification of cerebrospinal fluid amyloid-β peptides in alzheimer's disease: c-terminal truncation relates to early measures of neurodegeneration. 4. Biomarkers in sporadic and familial alzheimer's disease. 5. High resolution discovery proteomics reveals candidate disease progression markers of alzheimer's disease in human cerebrospinal fluid. 6. Label-free quantitative proteomics of mouse cerebrospinal fluid detects β-site app cleaving enzyme (bace1) protease substrates in vivo. 7. Dickkopf-related protein 3 is a potential aβ-associated protein in alzheimer's disease. 8. Soluble bace-1 activity and saβppβ concentrations in alzheimer's disease and age-matched healthy control cerebrospinal fluid from the alzheimer's disease neuroimaging initiative-1 baseline cohort. 9. [Development and evaluation of a multiplexed mass spectrometry based assay for measuring candidate peptide biomarkers in alzheimer's disease neuroimaging initiative (adni) csf.](https://www.ncbi.nlm.nih.gov/pubmed/25676562) 10. [An integrated workflow for multiplex csf proteomics and peptidomics-identification of candidate cerebrospinal fluid biomarkers of alzheimer's disease.](https://www.ncbi.nlm.nih.gov/pubmed/25490617) 11. [Proteomic analysis of cerebrospinal fluid in alzheimer's disease: wanted dead or alive.](https://www.ncbi.nlm.nih.gov/pubmed/25428253) 12. [Peripheral α-defensins 1 and 2 are elevated in alzheimer's disease.](https://www.ncbi.nlm.nih.gov/pubmed/25408207) 13. [Alzheimer amyloid peptide aβ42 regulates gene expression of transcription and growth factors.](https://www.ncbi.nlm.nih.gov/pubmed/25318543) 14. [A candidate plasma protein classifier to identify alzheimer's disease.](https://www.ncbi.nlm.nih.gov/pubmed/25114072) | **2015** |
| 1. [Differentially charged isoforms of apolipoprotein e from human blood are potential biomarkers of alzheimer's disease.](https://www.ncbi.nlm.nih.gov/pubmed/25478016) 2. [Identification and characterization of aβ peptide interactors in alzheimer's disease by structural approaches.](https://www.ncbi.nlm.nih.gov/pubmed/25346686) 3. [Identification of longitudinally dynamic biomarkers in alzheimer's disease cerebrospinal fluid by targeted proteomics.](https://www.ncbi.nlm.nih.gov/pubmed/24902845) 4. [Longitudinal effects of intravenous immunoglobulin on alzheimer's cerebrospinal fluid proteome.](https://www.ncbi.nlm.nih.gov/pubmed/24756957) 5. [Distinct transthyretin oxidation isoform profile in spinal fluid from patients with alzheimer's diseaseand mild cognitive impairment.](https://www.ncbi.nlm.nih.gov/pubmed/24678637) 6. [Altered levels of amyloid precursor protein intracellular domain-interacting proteins in alzheimer disease.](https://www.ncbi.nlm.nih.gov/pubmed/24077017) | **2014** |
| 1. [Targeted human cerebrospinal fluid proteomics for the validation of multiple alzheimer's disease biomarker candidates.](https://www.ncbi.nlm.nih.gov/pubmed/23735279) 2. [Semiquantitative proteomic analysis of human hippocampal tissues from alzheimer's disease and age-matched control brains.](https://www.ncbi.nlm.nih.gov/pubmed/23635041) 3. [Heart-type fatty acid binding protein and vascular endothelial growth factor: cerebrospinal fluidbiomarker candidates for alzheimer's disease.](https://www.ncbi.nlm.nih.gov/pubmed/23591828) 4. [Translational proteomics in alzheimer's disease and related disorders.](https://www.ncbi.nlm.nih.gov/pubmed/23089105) 5. Quantitative characterization of glycoproteins in neurodegenerative disorders using itraq. | **2013** |
| 1. [Distinct cerebrospinal fluid amyloid-beta peptide signatures in cognitive decline associated with alzheimer's disease and schizophrenia.](https://www.ncbi.nlm.nih.gov/pubmed/23161113) 2. Quantitative proteomic analysis of niemann-pick disease, type c1 cerebellum identifies protein biomarkers and provides pathological insight. 3. [Total apoe and apoe4 isoform assays in an alzheimer's disease case-control study by targeted mass spectrometry (n=669): a pilot assay for methionine-containing proteotypic peptides.](https://www.ncbi.nlm.nih.gov/pubmed/22918225) 4. [Plasma biomarkers associated with the apolipoprotein e genotype and alzheimer disease.](https://www.ncbi.nlm.nih.gov/pubmed/22801723) 5. Multi-source feature learning for joint analysis of incomplete multiple heterogeneous neuroimaging data. 6. [Can apolipoproteins and complement factors be biomarkers of alzheimer's disease?](https://www.ncbi.nlm.nih.gov/pubmed/22631439) 7. [A novel peptidomics approach to detect markers of alzheimer's disease in cerebrospinal fluid.](https://www.ncbi.nlm.nih.gov/pubmed/22465281) 8. [Proteomic changes in cerebrospinal fluid of presymptomatic and affected persons carrying familial alzheimer disease mutations.](https://www.ncbi.nlm.nih.gov/pubmed/22232349) 9. [Identification of sparc-like 1 protein as part of a biomarker panel for alzheimer's disease in cerebrospinal fluid.](https://www.ncbi.nlm.nih.gov/pubmed/22045497) 10. [Apolipoprotein ε4 modulates phenotype of butyrylcholinesterase in csf of patients with alzheimer's disease.](https://www.ncbi.nlm.nih.gov/pubmed/22012848) | **2012** |
| 1. [Peptide fingerprinting of alzheimer's disease in cerebrospinal fluid: identification and prospective evaluation of new synaptic biomarkers.](https://www.ncbi.nlm.nih.gov/pubmed/22046305) 2. Modeling of pathological traits in alzheimer's disease based on systemic extracellular signaling proteome. 3. Site-specific characterization of threonine, serine, and tyrosine glycosylations of amyloid precursor protein/amyloid beta-peptides in human cerebrospinal fluid. 4. [Multiplexed immunoassay panel identifies novel csf biomarkers for alzheimer's diseasediagnosis and prognosis.](https://www.ncbi.nlm.nih.gov/pubmed/21526197) 5. [Combined measurement of pedf, haptoglobin and tau in cerebrospinal fluid improves the diagnostic discrimination between alzheimer's disease and other dementias.](https://www.ncbi.nlm.nih.gov/pubmed/21323605) | **2011** |
| 1. [YKL-40: a novel prognostic fluid biomarker for preclinical alzheimer's disease.](https://www.ncbi.nlm.nih.gov/pubmed/21035623) 2. Ethylenediaminetetraacetic acid increases identification rate of phosphoproteomics in real biological samples. 3. MSQ: a tool for quantification of proteomics data generated by a liquid chromatography/matrix-assisted laser desorption/ionization time-of-flight tandem mass spectrometry based targeted quantitative proteomics platform. 4. [A novel abeta isoform pattern in csf reflects gamma-secretase inhibition in alzheimer disease.](https://www.ncbi.nlm.nih.gov/pubmed/20350302) 5. Analysis of human tau in cerebrospinal fluid. | **2010** |
| 1. [Identifying early markers of alzheimer's disease using quantitative multiplex proteomic immunoassay panels.](https://www.ncbi.nlm.nih.gov/pubmed/19906261) 2. [Proteomic analysis of protein profiles in some pathological stages of the human organism]. 3. [Proteomics-derived cerebrospinal fluid markers of autopsy-confirmed alzheimer's disease.](https://www.ncbi.nlm.nih.gov/pubmed/19863188) 4. [Multimodal techniques for diagnosis and prognosis of alzheimer's disease.](https://www.ncbi.nlm.nih.gov/pubmed/19829371) 5. [Proteomic analysis of alzheimer's disease cerebrospinal fluid from neuropathologically diagnosed subjects.](https://www.ncbi.nlm.nih.gov/pubmed/19689240) 6. [Long-term statin therapy and csf cholesterol levels: implications for alzheimer's disease.](https://www.ncbi.nlm.nih.gov/pubmed/19478483) 7. Novel t719p abetapp mutation unbalances the relative proportion of amyloid-beta peptides. 8. Quantitative profiling of polar cationic metabolites in human cerebrospinal fluid by reversed-phase nanoliquid chromatography/mass spectrometry. | **2009** |
| 1. [Both plasma retinol-binding protein and haptoglobin precursor allele 1 in csf: candidate biomarkers for the progression of normal to mild cognitive impairment to alzheimer's disease.](https://www.ncbi.nlm.nih.gov/pubmed/18378077) 2. [CSF multianalyte profile distinguishes alzheimer and parkinson diseases.](https://www.ncbi.nlm.nih.gov/pubmed/18343778) 3. iTRAQpak: an r based analysis and visualization package for 8-plex isobaric protein expression data. | **2008** |
| 1. [A novel panel of cerebrospinal fluid biomarkers for the differential diagnosis of alzheimer's disease versus normal aging and frontotemporal dementia.](https://www.ncbi.nlm.nih.gov/pubmed/17971664) 2. [Identification and validation of novel csf biomarkers for early stages of alzheimer's disease.](https://www.ncbi.nlm.nih.gov/pubmed/21136637) 3. [8-Plex quantitation of changes in cerebrospinal fluid protein expression in subjects undergoing intravenous immunoglobulin treatment for alzheimer's disease.](https://www.ncbi.nlm.nih.gov/pubmed/17880003) 4. Urea-based two-dimensional electrophoresis of beta-amyloid peptides in human plasma: evidence for novel abeta species. 5. [Fibrinogen gamma-a chain precursor in csf: a candidate biomarker for alzheimer's disease.](https://www.ncbi.nlm.nih.gov/pubmed/17565664) 6. [Proteomic discovery of csf biomarkers for alzheimer's disease.](https://www.ncbi.nlm.nih.gov/pubmed/17358005) 7. [Novel panel of cerebrospinal fluid biomarkers for the prediction of progression to alzheimerdementia in patients with mild cognitive impairment.](https://www.ncbi.nlm.nih.gov/pubmed/17353378) 8. [Multiplexed proteomic analysis of oxidation and concentrations of cerebrospinal fluid proteins in alzheimer disease.](https://www.ncbi.nlm.nih.gov/pubmed/17289803) 9. [Crebrospinal fluid proteomic biomarkers for alzheimer's disease.](https://www.ncbi.nlm.nih.gov/pubmed/17167789) | **2007** |
| 1. [Differential post-translational modifications of transthyretin in alzheimer's disease: a study of the cerebral spinal fluid.](https://www.ncbi.nlm.nih.gov/pubmed/16552785) 2. [Comparative proteomics of cerebrospinal fluid in neuropathologically-confirmed alzheimer's disease and non-demented elderly subjects.](https://www.ncbi.nlm.nih.gov/pubmed/16551433) 3. Detection of biomarkers with a multiplex quantitative proteomic platform in cerebrospinal fluid of patients with neurodegenerative disorders. 4. [Proteome studies of csf in ad patients.](https://www.ncbi.nlm.nih.gov/pubmed/16293296) | **2006** |
| 1. [Proteomic biomarker discovery in cerebrospinal fluid for neurodegenerative diseases.](https://www.ncbi.nlm.nih.gov/pubmed/16556969) 2. Comparative proteomic analysis of intra- and interindividual variation in human cerebrospinal fluid. 3. [Biomarkers for alzheimer's disease--clinical needs and application.](https://www.ncbi.nlm.nih.gov/pubmed/16556965) 4. [Quantitative proteomics of cerebrospinal fluid from patients with alzheimer disease.](https://www.ncbi.nlm.nih.gov/pubmed/15851850) | **2005** |
| 1. [Proteomic studies of potential cerebrospinal fluid protein markers for alzheimer's disease.](https://www.ncbi.nlm.nih.gov/pubmed/14559363) 2. [A panel of cerebrospinal fluid potential biomarkers for the diagnosis of alzheimer's disease.](https://www.ncbi.nlm.nih.gov/pubmed/12923774) | **2003** |
| 1. [Studies of potential cerebrospinal fluid molecular markers for alzheimer's disease.](https://www.ncbi.nlm.nih.gov/pubmed/12210229) | **2002** |